Summary & Overview
HCPCS J0894: Decitabine Injection, 1 mg
HCPCS Level II code J0894 designates a 1 mg unit of decitabine for injection, a cytotoxic agent used in the treatment of hematologic malignancies. As a drug-specific HCPCS code, J0894 is central to billing for decitabine when administered in infusion centers, physician offices, and outpatient hospital settings. Accurate coding ensures claims reflect the exact drug units administered and supports appropriate payer adjudication and utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of how J0894 is used in clinical billing, what benchmarks and coverage patterns typically influence reimbursement, and relevant policy considerations that can affect prior authorization and site-of-service decisions. The summary highlights typical sites of service and the clinical context in which decitabine is administered.
This publication is intended to inform billing professionals, practice managers, and revenue-cycle stakeholders about the practical implications of using HCPCS Level II code J0894, including unit-level reporting, common billing scenarios, and areas where payers often apply specific coverage rules or require additional documentation.
Billing Code Overview
HCPCS Level II code J0894 represents Injection, decitabine, 1 mg, a chemotherapy drug administration item used in oncology care. The service type is drug administration / injectable chemotherapy, typically delivered in oncology infusion centers, hospital outpatient departments, or physician offices depending on clinical setting and payer policies.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient with myelodysplastic syndrome or acute myeloid leukemia presents to an outpatient oncology infusion center for disease-directed therapy. The oncology team prescribes intravenous decitabine dosed per body surface area; the pharmacy dispenses the vial strength and documents amount administered in milligrams. A certified oncology nurse verifies identity, obtains baseline labs (CBC with differential, comprehensive metabolic panel), reviews prior neutrophil/platelet trends, and assesses for active infection. The nurse prepares the J0894 product (decitabine, 1 mg) in an appropriate diluent, programs the infusion pump, and administers the medication via peripheral IV or implanted port. During and after infusion, the patient is monitored for infusion reactions, cytopenia-related complications, and electrolyte abnormalities. Post-infusion documentation includes lot number, NDC, exact mg administered, route, site of service, and applicable modifier to reflect circumstances (for example, bilateral administration is not typical; common site of service is Outpatient Hospital (or Ambulatory Infusion Center) or Physician Office). Pharmacy/infusion billing submits HCPCS code J0894 with the correct quantity representing milligrams administered and links the service to the appropriate ICD-10 diagnosis for coverage and medical necessity review.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug wastage discarded | When part of a single-use vial of decitabine is discarded and payer allows reporting wastage |
JZ | No drug administered | When zero drug was administered despite preparation |
Q1 | Single-use vial discarded, no vial sharing | To indicate wastage from a single-use vial per payer policy |
62 | Two surgeons | Rarely used; only if two physicians of different specialties actively perform separate portions of care (not typical for infusion) |
78 | Unplanned return to OR | Not typically used; list if a post-procedure complication required return to operating room |
80 | Assistant surgeon | Not applicable for infusion; included only when an assistant surgeon is involved in a related invasive procedure |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Not typical for infusion-only encounters |
52 | Reduced services | When the decitabine infusion or associated service is partially reduced or not completed as originally planned |
53 | Discontinued procedure | When the infusion was initiated but discontinued due to patient instability or reaction |
22 | Unusual procedural services | When additional work, time, or complexity beyond typical infusion is required (document rationale) |
23 | Unusual anesthesia | If significant anesthesia was required beyond standard local measures for an associated invasive procedure |
QK | Anesthesia assistant certification on file | Use when applicable to billing for anesthesia services related to a procedure on the same day |
QX | Certified registered nurse anesthetist (CRNA) service with medical direction | When CRNA provides services under required supervision |
QY | Medical direction by physician of two, three, or four concurrent anesthesia procedures | When physician directs multiple concurrent anesthesia services |
TB | Intravenous infusion or injection administration by outpatient hospital | To indicate outpatient hospital-based administration when required by payer |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
208000000X | Hematology-Oncology | Medical oncologists and hematologist-oncologists who prescribe and oversee decitabine therapy |
207RC0000X | Internal Medicine — Hematology | Internists with hematology focus who manage marrow failure disorders and leukemia |
363L00000X | Oncology (Infusion) Nurse Specialist | Advanced practice nurses and infusion specialists administering chemotherapy |
3336C0003X | Clinical Pharmacology | Oncology pharmacists responsible for chemotherapy preparation, dosing, and verification |
282N00000X | Physician Assistant | PAs who assist in oncology clinics and manage infusion follow-up |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C92.10 | Acute myeloblastic leukemia not having achieved remission | Decitabine is used as cytotoxic therapy for AML, particularly in older patients or those unfit for intensive chemotherapy |
C94.40 | Myelodysplastic/myeloproliferative disease, with unspecified morphology | Hypomethylating agents like decitabine are standard therapy for higher-risk MDS |
D46.9 | Myelodysplastic syndrome, unspecified | Decitabine is indicated for treatment of myelodysplastic syndromes to improve cytopenias and alter disease course |
C92.00 | Acute myeloblastic leukemia not having achieved remission, without maturation | Represents AML subtypes treated with hypomethylating agents when appropriate |
D61.9 | Aplastic anemia, unspecified | Supportive consideration: while not a direct indication, decitabine may be used in differential bone marrow disorder management discussions |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96365 | Intravenous infusion, therapeutic, prophylactic, or diagnostic; initial, up to 1 hour | Used for billing the administration time for an initial decitabine infusion session when infusion duration fits the code definition |
96366 | Intravenous infusion, each additional hour | Used to report additional hours of infusion time beyond the initial unit if infusions extend longer than the base unit |
96413 | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to primary) | Used when multiple separate chemotherapy agents are administered sequentially during the same visit |
96374 | Therapeutic, prophylactic, or diagnostic injection (specify substance) subcutaneous or intramuscular | Used if an adjunct supportive medication is given subcutaneously or intramuscularly during the visit |
36415 | Collection of venous blood by venipuncture | Performed for necessary pre-infusion laboratory monitoring and billed as a separate service when appropriate |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | For administration of supportive injections (e.g., antiemetics) given during the infusion encounter |